Clinical Trial

A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

Completed Phase 2
View on ClinicalTrials.gov →
Summary
This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for chronic weight management in adult participants with obesity or overweight with at least one weight-related comorbidity, but without diabetes mellitus.
Protocol Amendment History 1 change
critical Trial completed 2026-07-30
Trial Details
NCT Number NCT07081958
Lead Sponsor Hoffmann-La Roche
Conditions Obesity or Overweight
Enrollment 352 participants
Start Date 2025-07-29
Primary Completion 2026-04-28 (estimated)
Study Completion 2026-07-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-29